On behalf of the entire CeCors and PsyKey team, we would like to express our deepest gratitude to our amazing shareholders for their patience and support this past year.
as head of Global Business Development; Dr. Michael J. McCarthy as an appointee to our Scientific Advisory Board; and Dr. Shahiem Hartley to our Medical Advisory Board.
Building a strong medical, scientific, and management team also continues to be a priority for the Company and was complemented by the 2022 additions of John Gustin
With our existing high-level political and celebrity backing, were confident we will hit our goal of enrolling 1 million veterans this year, concluded Kate Monroe.
Concurrent with closing, Kate Monroe will step in as CEO of CeCors, Inc., and VetComm will operate as a wholly-owned subsidiary. Operations of the controlled subsidiary PsyKey, Inc. will continue to run in parallel.
The idea of being involved with a public company only enhances our platform to get our message out to the over 14 million veterans who are entitled to compensation.